EDIT News and Press, Editas Medicine Inc. From 10/24/23

2023-10-24 08:05:14 ET More on Beam, CRISPR, etc. Beam: Opportunity Based On SCD Data Readout In 2024 Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy Editas Medicine: A Mispriced Contender In The Gene Editing Arena Beam extend...

2023-10-18 11:05:28 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sic...

2023-10-16 09:44:49 ET More on Editas Medicine Editas Medicine: A Mispriced Contender In The Gene Editing Arena Editas Medicine: RUBY Gems, Sparkling Catalysts In Sickle Cell Arena Editas gains as Stifel upgrades on sickle cell disease potential For further d...

CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, ge...

2023-10-11 11:07:37 ET Summary Editas Medicine specializes in gene editing, targeting a range of serious illnesses, with a unique platform that covers over 95% of the human genome. EDIT's collaboration with Bristol-Myers Squibb aims to revolutionize cancer treatments, especially i...

2023-10-03 02:59:03 ET Summary Editas Medicine's reduced R&D costs and strong cash position provide operational comfort but necessitate future capital, especially amid looming competition from exa-cel. EDIT-301 shows early promise in sickle cell disease, pivotal for Editas' va...

2023-10-02 10:00:00 ET If you've ever thought about investing in the gene-editing biotech space, Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) are doubtlessly familiar to you. While neither company is selling anything as of yet, in a few short months ...

2023-09-29 11:50:00 ET Summary The Fed's favorite inflation gauge falls below 4% for the first time in two years. Blue Apron to be acquired by Wonder Group for $13 per share. Market in the middle of "worst seasonal trends" of the year, but it is statistically normal - Goldman ...

Editas Medicine, Inc. (NASDAQ: EDIT) is one of today's top gainers. The company's shares are currently up 8.66% on the day to $7.52. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It d...

2023-09-29 07:49:11 ET More on Editas Editas Medicine, Inc. (EDIT) Cantor Global Healthcare Conference 2023 - (Transcript) Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill Presents at Morgan Stanley 21st Annual Global Healthcare Conference (Transcript) Editas Medicin...